Global Viral Vectors-based Gene Therapy for Non-human Primates Market to Reach US$ 92.76 Mn by 2034, Expanding at 11.0% CAGR

The global viral vectors-based gene therapy for non-human primates (NHPs) market is witnessing strong expansion as gene therapy research advances and demand for sophisticated preclinical models increases. Valued at US$ 29.97 Mn in 2023, the market is projected to expand at a CAGR of 11.0% from 2024 to 2034, reaching more than US$ 92.76 Mn by the end of 2034.

The market is being supported by growing investment in gene therapy research, expanding therapeutic applications of viral vectors, and increasing demand for non-human primate models to evaluate the safety, efficacy, biodistribution, and immune responses associated with emerging treatments.

Explore the highlights and essential data from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86394

Market Overview: Viral vectors play an important role in gene therapy by enabling the delivery of therapeutic genetic material into target cells. As researchers develop treatments for genetic disorders, infectious diseases, cancer, and neurodegenerative conditions, the need for reliable preclinical testing platforms is increasing.

Non-human primates are particularly valuable in translational research because of their close genetic and physiological similarities to humans. Their use allows researchers to generate important insights into vector performance, immune responses, tissue targeting, and therapeutic gene expression before advancing candidates into human clinical trials.
Continued development of advanced viral vectors, particularly adeno-associated virus (AAV) platforms, is therefore expected to create sustained demand for NHP-based gene therapy studies through 2034.

Key Players and Industry Leaders
Prominent companies operating in or contributing to this market include CRISPR Therapeutics, Voyager Therapeutics, Inc., Sarepta Therapeutics, Inc., Neuracle Genetics Inc., Beacon Therapeutics, REGENXBIO Inc., 4D Molecular Therapeutics, and Rocket Pharmaceuticals, Inc.

These companies are focusing on areas including next-generation vector development, targeted gene delivery, therapeutic development, vector optimization, and preclinical validation. Collaborations between biotechnology companies, pharmaceutical manufacturers, academic institutions, and contract research organizations are also strengthening the market ecosystem.

Key Drivers of Market Growth

Three major factors are expected to propel market expansion:
Increasing R&D activities: Growing investment in gene therapy research is increasing the number of preclinical programs requiring NHP models and viral-vector evaluation.

Expanding therapeutic applications: Viral vectors are increasingly being investigated for rare genetic diseases, cancer, infectious diseases, neurological disorders, ophthalmic conditions, and other indications.
Rising funding for NHP models: Increased investment in translational research and preclinical infrastructure is supporting demand for sophisticated NHP studies.
Advancements in AAV and gene-editing technologies, including CRISPR-based approaches, are further improving the precision of gene delivery and broadening the scope of potential therapeutic applications.

Key Market Highlights

The Adeno-associated Vectors segment is expected to dominate the market by vector type during the forecast period. AAV platforms are receiving substantial research attention because of their ability to deliver therapeutic genes to specific tissues and their applicability across a broad range of indications.
The Rhesus Macaques segment is projected to lead the market by NHP type. Their close genetic and physiological relationship with humans makes them valuable models for assessing gene therapy safety, efficacy, immune responses, and gene expression.

North America is expected to maintain its leading position through 2034, supported by a strong biotechnology ecosystem, significant research funding, established pharmaceutical companies, and advanced preclinical research infrastructure.

Visit our report to explore critical insights and analysis - https://www.transparencymarketresearch.com/viral-vectors-based-gene-therapy-for-non-human-primates-market.html

Market Trends & Innovations

The market is experiencing rapid innovation in vector engineering and targeted delivery technologies. Next-generation AAV capsids are being developed to improve tissue targeting, transduction efficiency, and therapeutic gene expression while addressing limitations associated with conventional vectors.
For example, in May 2024, Capsida Biotherapeutics reported preclinical data for CAP-002, an AAV-based gene therapy candidate targeting STXBP1 encephalopathy. According to the supplied market information, a single intravenous infusion produced widespread STXBP1 expression in the brain and transduced up to 70% of neurons at therapeutically relevant doses in NHPs.
Similarly, research published in 2022 by investigators at Mass Eye and Ear demonstrated the potential of combining the synthetic AAV vector Anc80L65 with a specialized surgical approach to deliver genetic material to the inner ear of NHPs. Such developments highlight the increasing focus on tissue-specific delivery and advanced vector technologies.

Key Investment Drivers

Investment opportunities are being created by the expanding gene therapy pipeline and increasing demand for high-quality viral vectors. Funding for vector manufacturing, capsid discovery, preclinical testing, and translational research is expected to remain important.

In January 2023, Vector BioMed launched with a US$ 15 Mn first financing round, according to the supplied information, to expand its lentiviral-vector manufacturing capabilities. Investments of this nature can strengthen the supply chain supporting preclinical and clinical gene therapy development.
Strategic partnerships and licensing agreements are another important investment driver. In July 2024, Abeona Therapeutics and Beacon Therapeutics announced an agreement under which Beacon would evaluate Abeona's patented AAV204 capsid for potential ophthalmology gene therapies.

New Opportunities and Challenges

The growing application of gene therapy in neurological, ophthalmic, oncological, infectious, and rare genetic diseases presents substantial opportunities. Emerging markets, improved vector manufacturing, advanced capsid engineering, and more sophisticated NHP study designs could further expand the market.

However, regulatory requirements, biosafety considerations, high research costs, and ethical concerns surrounding NHP research remain significant challenges. Researchers and industry participants must also address vector immunogenicity, manufacturing scalability, tissue-specific delivery, and reproducibility of preclinical outcomes.

Buy this Premium Research Report for exclusive, in-depth insights - https://www.transparencymarketresearch.com/checkout.php?rep_id=86394<ype=S

Future Outlook

The viral vectors-based gene therapy for non-human primates market is expected to maintain strong momentum through 2034. Continued development of AAV and other viral-vector technologies, coupled with expanding gene therapy pipelines, is likely to increase demand for NHP-based preclinical studies.
As pharmaceutical and biotechnology companies seek more predictive translational models, NHP studies are expected to remain an important component of gene therapy development. North America is likely to remain the leading regional market, while opportunities across Europe and Asia Pacific are expected to increase as research capabilities and investment expand.

Market Segmentation

The market can be segmented as follows:
By Type of Vector: Adenoviral Vectors, Adeno-associated Vectors, Retroviral Vectors, Lentiviral Vectors, and Other Vectors.

By Type of Non-human Primate: Marmosets, Rhesus Macaques, Cynomolgus Monkeys, and Others.

By Therapeutic Area: Genetic Disorders, Infectious Diseases, Oncological Disorders, Neurodegenerative Disorders, and Other Disorders.

By End-user: Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic and Research Institutes.

By Region: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Important FAQs

What was the global market size in 2023?
The global viral vectors-based gene therapy for non-human primates market was valued at US$ 29.97 Mn in 2023.

What will the market size be in 2034?
The market is projected to reach more than US$ 92.76 Mn by 2034.

What is the expected CAGR?
The market is projected to grow at a CAGR of 11.0% from 2024 to 2034.

What are the major market drivers?
Key drivers include increasing R&D activities, expanding therapeutic applications of viral vectors, and rising funding for NHP models.

Which vector segment is expected to dominate?
The Adeno-associated Vectors (AAV) segment is projected to dominate the market.

Which NHP segment is expected to lead?
Rhesus Macaques are expected to account for the leading share because of their genetic and physiological similarities to humans.

Which region is expected to dominate the market?
North America is expected to maintain the largest market share during the forecast period.

Who are the prominent market players?
Major companies include CRISPR Therapeutics, Voyager Therapeutics, Sarepta Therapeutics, Neuracle Genetics, Beacon Therapeutics, REGENXBIO, 4D Molecular Therapeutics, and Rocket Pharmaceuticals.

Explore Latest Research Reports by Transparency Market Research

Sterilization Wrap Market: https://www.transparencymarketresearch.com/sterilization-wrap-market.html

Heparin Market: https://www.transparencymarketresearch.com/heparin-market.html

Skin Antiseptic Market: https://www.transparencymarketresearch.com/skin-antiseptic-market.html

Influenza Vaccine Market: https://www.transparencymarketresearch.com/influenza-vaccine-market.html

About Us Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com

This release was published on openPR.